Abstract
The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have